Clearview Wealth Advisors’s Emergent Biosolutions EBS Stock Holding History

Clearview Wealth Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-200	Closed	-$1.47K	–	257
2023 Q2	$1.47K	Hold	200	–	–	﹤0.01%	558
2023 Q1	$2.07K	Hold	200	–	–	﹤0.01%	517
2022 Q4	$2.36K	Hold	200	–	–	﹤0.01%	466
2022 Q3	$4K	Hold	200	–	–	﹤0.01%	423
2022 Q2	$6K	Hold	200	–	–	﹤0.01%	412
2022 Q1	$8K	Hold	200	–	–	0.01%	410
2021 Q4	$9K	Hold	200	–	–	0.01%	432
2021 Q3	$10K	Hold	200	–	–	0.01%	416
2021 Q2	$13K	Hold	200	–	–	0.01%	383
2021 Q1	$19K	Hold	200	–	–	0.01%	338
2020 Q4	$18K	Buy	+200	New	+$18.4K	0.01%	313

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Clearview Wealth Advisors's EBS Position: Q3 2023 in Review

Clearview Wealth Advisors sold out of Emergent Biosolutions (EBS) in Q3 2023, closing a stake of 200 shares — an estimated $1.47K sold.

Clearview Wealth Advisors first reported a position in EBS in Q4 2020 and held it in 11 quarters. The position peaked at $19K in Q1 2021. 162 funds tracked by Wall St. Rank hold EBS as of Q3 2023.

Clearview Wealth Advisors reported no remaining Emergent Biosolutions position as of Q3 2023 after selling out during the quarter.
Clearview Wealth Advisors sold 200 Emergent Biosolutions shares in Q3 2023, an estimated $1.47K.
Clearview Wealth Advisors first reported a position in Emergent Biosolutions in Q4 2020 and held it in 11 quarters.
Clearview Wealth Advisors's Emergent Biosolutions position peaked at $19K in Q1 2021.
162 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2023.

Based on Clearview Wealth Advisors's 13F filing for Q3 2023, filed 30 Oct 2023.